Search results for "Injection"

showing 10 items of 920 documents

A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in pati…

1993

After informed consent, 86 patients with advanced cancer undergoing potentially myelosuppressive cytotoxic chemotherapy were randomized to receive placebo or subcutaneous granulocyte - colony stimulating factor (G- CSF) 5 μg/Kg/day in order to prevent severe neutropenia and its related morbidity. The incidence of neutropenia (absolute neutrophil count <1, 000/mm3) was significantly reduced in patients receiving G-CSF than in controls (18% versus 42%; P <0.05). The duration of neutropenia was also shortened by the administration of G-CSF (4.8 versus 8.2 days; P <0.05). Therapy with G-CSF has also a positive impact on the dose-intensity of employed regimens. Patients treated with G-CSF showed…

AdultMale0301 basic medicineMicrobiology (medical)medicine.medical_specialtyNeutropeniaTime FactorsFeverInjections Subcutaneousmedicine.medical_treatment030106 microbiologyAntineoplastic AgentsNeutropeniaGranulocytePlaceboGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansPharmacology (medical)Prospective StudiesNeoplasm MetastasisAgedPharmacologyChemotherapybusiness.industryIncidenceIncidence (epidemiology)CarcinomaMiddle Agedmedicine.diseaseRecombinant ProteinsGranulocyte colony-stimulating factorSurgeryInfectious DiseasesGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureOncology030220 oncology & carcinogenesisAbsolute neutrophil countFemalebusinessmedicine.drug
researchProduct

Correlation between the DNA fragmentation index (DFI) and sperm morphology of infertile patients

2020

Abstract Purpose To evaluate the correlation between the DNA Fragmentation Index (DFI) and sperm morphology in patients undergoing ICSI, as a predictive parameter in reproductive outcomes. Methods A retrospective study was conducted on 125 infertile patients enrolled in a fertility clinic. Seminal characteristics were measured following the WHO guidelines (2010) for the examination of the seminal fluid. After collecting motile sperm population by pellet swim up, DFI was calculated and simultaneously associated with sperm morphology using in situ TUNEL assay and an image analyzer software in at least 250 spermatozoa for each patient. Results All subjects were divided into two groups accordin…

AdultMale0301 basic medicineSettore MED/07 - Microbiologia E Microbiologia ClinicaPopulationStatistical differenceHuman spermatozoaSperm morphologyDNA FragmentationFertilization in VitroBiologyPellet Swim upAndrologyCorrelation03 medical and health sciences0302 clinical medicineSemenGamete BiologyGeneticsmedicineHumansSperm Injections IntracytoplasmicSettore BIO/06 - Anatomia Comparata E CitologiaeducationInfertility MaleGenetics (clinical)education.field_of_study030219 obstetrics & reproductive medicineSperm CountSpermatozoonurogenital systemObstetrics and GynecologyMotile spermGeneral MedicineTUNEL assaySpermatozoaSperm030104 developmental biologymedicine.anatomical_structureReproductive MedicineSperm morphologyDNA fragmentationDFIDNA DamageDevelopmental BiologyJournal of Assisted Reproduction and Genetics
researchProduct

Gonadotropin Secretion in Eugonadotropic Human Males and Postmenopausal Females Under Long Term Application of a Potent Analog of Gonadotropin-Releas…

1978

Long-acting analogs are of special interest in long-term treatment with gonadotropin-releasing hormone (GnRH). However, inhibitory effects of agonist analogs on gonadotropin secretion or on reproductive processes have been observed in rats as well as in human males. Since these inhibitory effects seem to be dose-related, we checked the findings for d-Leu 6 -des-Gly 10 -GnRH-ethylamide within the dose range proposed by us for treatment. In six eugonadotropic human males, a significant decrease of luteinizing hormone and follicle-stimulating hormone responsiveness to a standard dose of GnRH and significant decrease of testosterone basal secretion were observed after 2 and 4weeks of subcutaneo…

AdultMaleAgonistendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classInjections SubcutaneousGonadotropin-releasing hormoneHuman MalesBiologyGonadotropin-Releasing HormoneBasal (phylogenetics)Internal medicinemedicineHumansTestosteroneAdministration IntranasalTestosteroneObstetrics and GynecologyLuteinizing HormoneGonadotropin secretionEndocrinologyReproductive MedicineFemaleFollicle Stimulating HormoneMenopauseLuteinizing hormonePituitary Hormone-Releasing Hormoneshormones hormone substitutes and hormone antagonistsHormoneFertility and Sterility
researchProduct

Lorcainide. I. Saturable presystemic elimination.

1979

AdultMaleBenzeneacetamidesAdministration OralPharmacologyHepatic VeinsIn Vitro TechniquesPulmonary ArteryLorcainidePiperidinesMedicineHumansPharmacology (medical)Aorta AbdominalAortaAgedPharmacologybusiness.industryArrhythmias CardiacBlood ProteinsMiddle AgedBloodInjections IntravenousAcetanilidesFemalebusinessAnti-Arrhythmia Agentsmedicine.drugProtein BindingClinical pharmacology and therapeutics
researchProduct

Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.

1989

The in vivo effect of yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) was investigated in 30 patients with advanced malignancy in a phase Ib trial. Patients were treated at four different dose levels (120 to 1,000 micrograms/m2/d) by either daily intravenous (IV) bolus injection or 24-hour continuous infusion. Administration of rh GM-CSF resulted in a broad spectrum of dose- and schedule-dependent hematopoietic effects. Sustained infusion of rh GM-CSF elicited a maximum 17-fold average peak increase of the total WBC count with mainly neutrophils, eosinophils, and monocytes accounting for this rise, and increases in bone marrow cellularity with a…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentMicrogramMalignancyDrug Administration ScheduleLeukocyte CountColony-Stimulating FactorsIn vivoBone MarrowInternal medicineNeoplasmsmedicineHumansPlateletLeukocytosisGrowth SubstancesInfusions IntravenousAgedbusiness.industryPlatelet CountGranulocyte-Macrophage Colony-Stimulating FactorMiddle Agedmedicine.diseaseRecombinant ProteinsHematopoiesisHaematopoiesisEndocrinologyGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureOncologyImmunologyInjections IntravenousDrug EvaluationFemalemedicine.symptombusinessmedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multic…

2006

BACKGROUND. To date, the standard treatment for patients who have carcinoma of unknown primary site has not been established. METHODS. In this randomized Phase II study, 66 previously untreated patients (33 patients per arm) with carcinomas of unknown primary site received cisplatin (35 mg/m2) and gemcitabine (1000 mg/m2) with either paclitaxel (70 mg/m2) or vinorelbine (25 mg/m2), and all drugs were administered intravenously on Days 1 and 8 of a 21-day cycle. Twenty-nine patients (44%) presented with ≥2 involved sites. The pathologic diagnosis was mainly adenocarcinoma (48 patients; 72.7%) and squamous carcinoma (7 patients; 10.6%). RESULTS. In the first arm, 16 patients (48.5%) experienc…

AdultMaleCancer Researchmedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentPhases of clinical researchVinorelbineVinblastineGastroenterologyDeoxycytidineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedChemotherapybusiness.industryStandard treatmentCarcinomaVinorelbineMiddle AgedGemcitabineGemcitabineSquamous carcinomaSurgeryRegimenOncologyTolerabilityItalyInjections IntravenousNeoplasms Unknown PrimaryFemaleCisplatinbusinessmedicine.drugCancer
researchProduct

Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study.

1998

The present phase II study was undertaken to assess antitumoral activity, safety and tolerability of recombinant human interleukin-6 (rh IL-6) in patients with advanced renal cell cancer. Rh IL-6 was administered as a daily subcutaneous injection at a fixed dose of 150 micrograms/day for a maximum of 42 consecutive days. 12 patients with metastatic renal cell cancer without previous immunotherapy were enrolled and were evaluated for response. No objective clinical responses were observed in the trial. Toxicity was moderate and reversible and mainly comprised fever, influenza-like symptoms, fatigue and moderate hepatotoxicity. Anaemia, leucocytosis, thrombocytosis and induction of an acute p…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchAntineoplastic AgentsGastroenterologySubcutaneous injectionInternal medicinemedicineHumansTreatment FailureCarcinoma Renal CellAgedKidneyThrombocytosisbusiness.industryInterleukin-6CancerImmunotherapyMiddle Agedmedicine.diseaseKidney NeoplasmsRecombinant Proteinsmedicine.anatomical_structureC-Reactive ProteinOncologyTolerabilityImmunologyFemalebusinessKidney diseaseEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Anterior limbic alpha-like activity: a low resolution electromagnetic tomography study with lorazepam challenge

2005

Summary Objective To verify findings of an independently regulated anterior limbic alpha band source. Methods In a randomised cross-over study, the spontaneous EEG was recorded in nine healthy subjects after i.v. lorazepam or placebo. Intracerebral current densities within classical frequency bands were estimated with low resolution electromagnetic tomography [LORETA] and compared between groups with t -statistical parametric mapping [SPM{ t }]. A region-of-interest [ROI] based method was used to compare frontal and occipital alpha band activity changes. Results Irrespective of treatment group, local maxima of alpha band power were localised both in the occipital lobe, Brodman area [BA] 18,…

AdultMaleCingulate cortexFrequency bandAlpha (ethology)ElectroencephalographyLorazepamStatistical parametric mappingStatistics NonparametricElectromagnetic FieldsNuclear magnetic resonanceLimbic systemPhysiology (medical)mental disordersLimbic SystemmedicineHumansSingle-Blind MethodAnterior cingulate cortexPhysicsCross-Over Studiesmedicine.diagnostic_testSensory SystemsAlpha Rhythmmedicine.anatomical_structureNeurologyInjections IntravenousNeurology (clinical)Occipital lobeNeuroscienceClinical Neurophysiology
researchProduct

High Iodine Concentration Contrast Material for Noninvasive Multislice Computed Tomography Coronary Angiography

2006

OBJECTIVE: The objective of this study was to compare intracoronary attenuation on 16-row multislice computed tomography (16-MSCT) coronary angiography using 2 contrast materials (CM) with high iodine concentration. MATERIAL AND METHODS: Forty consecutive patients (29 male, 11 female; mean age, 61 ± 11 years) with suspected coronary artery disease were randomized to 2 groups to receive 100 mL of either iopromide 370 (group 1: Ultravist 370, 370 mg iodine/mL; Schering AG, Berlin, Germany) or iomeprol 400 (group 2: Iomeron 400, 400 mg iodine/mL; Bracco Imaging SpA, Milan, Italy). Both CM were administered at a rate of 4 mL/s. All patients underwent 16-MSCT coronary angiography (Sensation 16; …

AdultMaleCoronary angiographymedicine.medical_specialtyIohexolmedia_common.quotation_subjectContrast MediaCoronary Artery DiseasemedicineHumansContrast (vision)Radiology Nuclear Medicine and imagingHigh iodineAgedmedia_commonbusiness.industryIopromideMean ageGeneral MedicineMultislice computed tomographyMiddle AgedIopamidolcontrast materialIomeprol 400Injections IntravenousFemaleRadiologyTomographycoronary angiographyTomography X-Ray Computediodine concentrationbusiness16-row multislice CTmedicine.drugInvestigative Radiology
researchProduct

Effects of Intravenous Corticotropin-Releasing Hormone upon Sleep-Related Growth Hormone Surge and Sleep EEG in Man

1988

Corticotropin-releasing hormone (CRH) plays a key role in coordinating neuroendocrine, metabolic and behavioral responses in stress and affective disorders. To further investigate the effects of enhanced pituitary-adrenocortical activity upon sleep-related phenomena we administered four intravenous injections of 50 micrograms human (h)-CRH or saline to 11 normal males at 10 p.m., 11 p.m., 12 p.m. and 1 a.m. and measured plasma levels of cortisol and growth hormone (GH) as well as sleep EEG recordings throughout the night. Treatment with h-CRH resulted in a significant increase of mean (+/- SEM) cortisol secretion between 11 p.m. and 3 a.m. (h-CRH: 100.6 +/- 9.5 ng/ml; saline: 39.0 +/- 1.5 n…

AdultMaleCortisol secretionendocrine systemmedicine.medical_specialtyCorticotropin-Releasing HormoneEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPituitary-Adrenal SystemPeptide hormoneCellular and Molecular NeuroscienceCorticotropin-releasing hormoneEndocrinologyInternal medicinemedicineHumansSalineSlow-wave sleepEndocrine and Autonomic SystemsChemistryElectroencephalographySleep in non-human animalsEndocrinologyGrowth HormoneInjections IntravenousSleepSleep eeghormones hormone substitutes and hormone antagonistsHormoneNeuroendocrinology
researchProduct